Long-Term Oral Bisphosphonate Compliance Focusing on Switching of Prescription Pattern

References

• Barrett-Connor E, Black D, Bonjour JP, et al. Prevention and management of osteoporosis. WHO Tech Rep Ser. 2003;921:1–164, back cover.
   Web of Science ®Google Scholar
• Consensus A. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94(6):646–650.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359(9319):1761–1767.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Denosumab: a review of its use in postmenopausal women with osteoporosis. Drugs Aging. 2014;31(7):555–576. doi:10.1007/s40266-014-0191-3
   Web of Science ®Google Scholar
• Park EJ, Joo IW, Jang MJ, Kim YT, Oh K, Oh HJ. Prevalence of osteoporosis in the Korean population based on Korea National Health and Nutrition Examination Survey (KNHANES), 2008–2011. Yonsei Med J. 2014;55(4):1049–1057. doi:10.3349/ymj.2014.55.4.1049
   Web of Science ®Google Scholar
• Park SB, Kim J, Jeong JH, et al. Prevalence and incidence of osteoporosis and osteoporotic vertebral fracture in Korea: Nationwide Epidemiological Study focusing on differences in socioeconomic status. Spine. 2016;41(4):328–336.
   Web of Science ®Google Scholar
• Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012;23(1):223–231. doi:10.1007/s00198-011-1535-z
   PubMed Web of Science ®Google Scholar
• Hoer A, Seidlitz C, Gothe H, et al. Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence. 2009;3:25–30.
   PubMed Web of Science ®Google Scholar
• Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009;122(2Suppl):S3–S13. doi:10.1016/j.amjmed.2008.12.002
   Web of Science ®Google Scholar
• Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin. 2007;23(3):585–594.
   PubMed Web of Science ®Google Scholar
• Cotte FE, Mercier F, De Pouvourville G. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. Clin Ther. 2008;30(12):2410–2422. doi:10.1016/j.clinthera.2008.12.019
   PubMed Web of Science ®Google Scholar
• Majumdar SR, Johnson JA, Lier DA, et al. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial. Osteoporos Int. 2007;18(3):261–270. doi:10.1007/s00198-006-0248-1
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15(12):1003–1008. doi:10.1007/s00198-004-1652-z
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013–1022. doi:10.4065/81.8.1013
   PubMed Web of Science ®Google Scholar
• Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165(20):2414–2419. doi:10.1001/archinte.165.20.2414
   PubMed Web of Science ®Google Scholar
• Silverman SL, Gold DT. Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep. 2008;10(2):118–122. doi:10.1007/s11926-008-0021-x
   Google Scholar
• Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Strom O. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int. 2015;26(10):2401–2411. doi:10.1007/s00198-015-3253-4
   Web of Science ®Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21(9):1453–1460. doi:10.1185/030079905X61875
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38(6):922–928. doi:10.1016/j.bone.2005.10.022
   Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381. doi:10.1007/s00198-014-2794-2
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535–1541. doi:10.1016/S0140-6736(96)07088-2
   PubMed Web of Science ®Google Scholar
• Papapoulos SE. Use of bisphosphonates in the management of postmenopausal osteoporosis. Ann N Y Acad Sci. 2011;1218:15–32. doi:10.1111/j.1749-6632.2010.05767.x
   PubMed Web of Science ®Google Scholar
• Rabenda V, Hiligsmann M, Reginster JY. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother. 2009;10(14):2303–2315. doi:10.1517/14656560903140533
   PubMed Web of Science ®Google Scholar
• Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18(8):1023–1031. doi:10.1007/s00198-006-0322-8
   PubMed Web of Science ®Google Scholar
• Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA. Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med. 2010;123(3):275–280. doi:10.1016/j.amjmed.2009.05.017
   PubMed Web of Science ®Google Scholar
• Cramer JA, Silverman SL, Gold DT. Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis. Curr Med Res Opin. 2007;23(10):2369–2377. doi:10.1185/030079907X226311
   PubMed Web of Science ®Google Scholar
• Li L, Roddam A, Ferguson S, Feudjo-Tepie M, Taylor A, Jick S. Switch patterns of osteoporosis medication and its impact on persistence among postmenopausal women in the U.K. General Practice Research Database. Menopause. 2014;21(10):1106–1113. doi:10.1097/GME.0000000000000214
   Web of Science ®Google Scholar
• Cheng LI, Durden E, Limone B, et al. Persistance and compliance with osteroporosis therapies among women in a commercially insured population in the United States. J Manag Care Spec Pharm. 2015;21(9):824–833, 833a. doi:10.18553/jmcp.2015.21.9.824
   PubMed Web of Science ®Google Scholar
• Cotte FE, Fardellone P, Mercier F, Gaudin AF, Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int. 2010;21(1):145–155.
   PubMed Web of Science ®Google Scholar
• Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006;17(11):1645–1652. doi:10.1007/s00198-006-0179-x
   Web of Science ®Google Scholar
• Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565–574;discussion 575–567. doi:10.1002/pds.1230
   Web of Science ®Google Scholar
• Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010;21(11):1943–1951. doi:10.1007/s00198-009-1134-4
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2008;19(4):511–517. doi:10.1007/s00198-007-0466-1
   PubMed Web of Science ®Google Scholar
• Lakatos P, Takacs I, Marton I, et al. A retrospective longitudinal database study of persistence and compliance with treatment of osteoporosis in Hungary. Calcif Tissue Int. 2016;98(3):215–225. doi:10.1007/s00223-015-0082-6
   Web of Science ®Google Scholar
• Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015;26(10):2479–2489. doi:10.1007/s00198-015-3164-4
   Web of Science ®Google Scholar
• Silverman SL, Siris E, Kendler DL, et al. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int. 2015;26(1):361–372. doi:10.1007/s00198-014-2871-6
   Web of Science ®Google Scholar
• Ideguchi H, Ohno S, Hattori H, Ishigatsubo Y. Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world. Osteoporos Int. 2007;18(10):1421–1427. doi:10.1007/s00198-007-0406-0
   Web of Science ®Google Scholar
• Iolascon G, Gimigliano F, Orlando V, Capaldo A, Di Somma C, Menditto E. Osteoporosis drugs in real-world clinical practice: an analysis of persistence. Aging Clin Exp Res. 2013;25(Suppl 1):S137–S141. doi:10.1007/s40520-013-0127-5
   Web of Science ®Google Scholar
• Cho H, Byun JH, Song I, et al. Effect of improved medication adherence on health care costs in osteoporosis patients. Medicine. 2018;97(30):e11470. doi:10.1097/MD.0000000000011470
   PubMed Web of Science ®Google Scholar